Reply to “Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma” by Mesbah Ardakani et al.
Pigment Cell & melanoma research . 30 ( 5 ) : 498-500
DOI: 10.1111/pcmr.12606
Article dans une revue
voir la publication